Clinical Trials Logo

Clinical Trial Summary

Diagnostic esophagogastroduodenoscopy is an uncomfortable and stressful procedure for most of the patients. Various methods are available for sedation during this procedure. Because of some side effects related to intravenous administration of sedatives, oral administration of these drugs is under attention. Alprazolam is a benzodiazepine which is used mainly in treatment of anxiety. Hence, we determine the efficacy of oral and sublingual alprazolam as for sedation during this procedure. We hypothesize that sublingual alprazolam is more effective than that oral form and both forms more effective than placebo in reducing anxiety and pain/discomfort related to the procedure.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Diagnostic Esophagogastroduodenoscopy

NCT number NCT01949038
Study type Interventional
Source Isfahan University of Medical Sciences
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 2011
Completion date January 2013

See also
  Status Clinical Trial Phase
Completed NCT03130842 - Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy Phase 2/Phase 3